EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients

Ci Shan, Zhe Wei, Shanshan Li, Zeng Zhang, Hua Yue, Weijia Yu, Qingcheng Yang, Zhenlin Zhang

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07527-9 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Osteoporosis International, 2025. Verfasst von Ci Shan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shang…. Hauptthemen laut MEDLINE: Paraneoplastic Syndromes, Neoplasms, Connective Tissue, Osteomalacia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We reported a single-center retrospective cohort study on 117 patients of Tumor‐induced osteomalacia (TIO) to summarize our experience with TIO over the past decade. The clinical characteristics, diagnosis, treatment and postoperative outcomes were analyzed. Together, our data demonstrate the characteristics and prognosis of TIO and unveil a possible TIO management process. TIO is a rare paraneoplastic syndrome that ultimately results in debilitating musculoskeletal deficits and regressive activity obstacles due to hypophosphatemia. The diagnosis and treatment of TIO are challenging owing to nonspecific symptoms, occult tumors and the lack of awareness. We aimed to summarize our experience with TIO over the past decade and to optimize its clinical management. A retrospective analysis was conducted of all patients with TIO admitted to our department and underwent surgical treatment at our hospital between 2012 and 2023. Clinical characteristics and postoperative outcomes were evaluated. A total of 117 patients with typical clinical characteristics were enrolled, manifesting diffuse bone pain, decreased serum phosphate and elevated serum intact fibroblast growth factor-23 (iFGF23). All the patients were managed using a stepwise pathway detailing diagnosis, identification of the causative tumors, operations and postoperative surveillance. The causative tumors were equally located in bone and soft tissues, and the main sites were the lower extremities and pelvis (63.2%). 117 cases were caused by phosphaturic mesenchymal tumors (PMTs), which were usually small and benign, with a median volume of 1.45cm 3 (IQR 0.70–4.17 cm 3 ) and low Ki67 labeling indices (< 10%, 91.7%). After surgery, the serum P became normal within 7 days in 82.7% of the cured patients; serum iFGF23 decreased rapidly in one day and then gradually increased to normal with other laboratory indices and bone mineral density. The median follow-up period was 12 months (range, 1–144), during which 19 patients remained uncured. Among them, 5 patients experienced local recurrence and 2 suffered distant metastases. Younger age, bone-derived tumors and malignant tumors were risk factors for adverse outcomes. Tumors located in the femoral head, acetabulum, and spine showed a higher risk of obstinacy among bone-derived tumors. TIO patients were able to benefit from the management including early recognition and diagnosis of the disease, identification and complete removal of the causative tumors, followed by regular postoperative surveillance. Of particular concern were patients with bone-derived tumors, who had high non-remission and recurrence rates. This study was registered with CHICTR.ORG.CN (ChiCTR2100042796).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Paraneoplastic SyndromesNeoplasms, Connective TissueOsteomalaciaHumansRetrospective StudiesFemaleMaleMiddle AgedAdultFibroblast Growth Factor-23AgedYoung AdultTreatment OutcomeFibroblast Growth FactorsHypophosphatemiaAdolescent

Stichwörter der Autor:innen

Clinical managementHypophosphatemiaRetrospective studyTumor-induced osteomalaciaTumors of soft tissue and bone

Substanzen

Fibroblast Growth Factor-23Fibroblast Growth Factors

Autor:innen und Institutionen

  • Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
  • Department of Orthopedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
  • Department of Osteoporosis and Bone Disease, Huadong Hospital, Fudan University, Shanghai, 200040, China.
  • Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.…

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission

Zitieren

APA

Shan, C., Wei, Z., Li, S., Zhang, Z., Yue, H., Yu, W., Yang, Q., & Zhang, Z. (2025). Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients. Osteoporosis International. https://doi.org/10.1007/s00198-025-07527-9

Vancouver

Shan C, Wei Z, Li S, Zhang Z, Yue H, Yu W, et al. Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients. Osteoporosis International. 2025. doi:10.1007/s00198-025-07527-9

BibTeX
@article{Shan2025,
  author = {Shan, Ci and Wei, Zhe and Li, Shanshan and Zhang, Zeng and Yue, Hua and Yu, Weijia and Yang, Qingcheng and Zhang, Zhenlin},
  title = {Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07527-9}
}
Kostenlos starten →